Trials
Ongoing trials:
First line of treatment
- Perseus - A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy
- Ixazomib-Revlimid-Dexamethason in first line for the young
- KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
- HOVON129 - Treatment of primary plasma cell leukemia
- Hovon147 - Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
Relapse or refractory, patient not eligible for ASCT
- Panorama 3: Panobinostat-Velcade-Dexamethason randomized to different doses in relapse treatment
- Melflufen vs Pomalidomide in relapsed myeloma
- Ixazomib vs Pomalidomide in relapsed myeloma
- Combined carfilzomib and hydroxychloroquine in patients with relapsed / refractory multiple myeloma – A phase I trial
- An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
- A Phase I, open-label, multicenter, study of WVT078 in subjects with relapsed and/or refractory multiple myeloma
- bb2121 - A phase 3, multicenter, randomized, openlabel study to compare the efficacy and safety of BB2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)
Upcoming trials:
- AN OPEN-LABEL, MULTICENTER, PHASE I TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7297089 IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA